Leaderboards/Amyloidosis: Diagnosis, Treatment, Outcomes

Amyloidosis: Diagnosis, Treatment, Outcomes

Last updated July 15, 2026

Rising Stars

Fresh ink, massive impact

Researchers

1
Xia Wu
Tufts Medical Center
2
Grant Duffy
Cedars-Sinai Medical Center
3
Sarah J. Doran
University of Cincinnati Medical Center
4
Liza Chacko
Imperial College London
5
Elena Solopova
Vanderbilt University Medical Center
6
Lynn Radamaker
Universität Ulm
7
Danah Al Shaer
Evotec (United Kingdom)
8
Karola Jering
Brigham and Women's Hospital
9
Muhammad U. Rauf
The Royal Free Hospital
10
Yousuf Razvi
The Royal Free Hospital

Papers

1
Publication in Frontiers in Neuroscience (2024) [100 citations, W4391033321]
Frontiers in Neuroscience|2024
100 cit.
2
Publication in Pharmaceuticals (2024) [90 citations, W4391821348]
Pharmaceuticals|2024
90 cit.
3
Myocardial Perfusion in Cardiac Amyloidosis
European Journal of Heart Failure|2024
40 cit.
4
Effects of vutrisiran on cardiac structure and function in patients with transthyretin amyloidosis with cardiomyopathy: secondary outcomes of the HELIOS-B trial
Nature Medicine|2025
17 cit.
5
Effects of Vutrisiran on Cardiac Function and Outcomes in Patients With Transthyretin Amyloidosis With Cardiomyopathy
Journal of the American College of Cardiology|2025
10 cit.
6
Publication in JACC. Cardiovascular imaging (2025) [9 citations, W4412196705]
JACC. Cardiovascular imaging|2025
9 cit.
7
Publication in JACC Heart Failure (2026) [3 citations, W7123360036]
JACC Heart Failure|2026
3 cit.
8
Publication in Journal of the American College of Cardiology (2025) [2 citations, W4408977221]
Journal of the American College of Cardiology|2025
2 cit.
9
NT-proBNP in the Early Convalescent Phase after High-Risk Myocardial Infarction Is Associated with Adverse Cardiovascular Outcomes: the PARADISE-MI Trial
Journal of Cardiac Failure|2025
2 cit.
10
Revised renal stratification and progression models for predicting long-term renal outcomes in immunoglobulin light chain amyloidosis
Haematologica|2025
2 cit.

Emerging Leaders

Drafting the new consensus

Researchers

1
Jonathan C. Fox
Fluidigm (United States)
2
Fernanda Bravo
University of California, Los Angeles
3
Roza Badr Eslam
Medical University of Vienna
4
Marianna Fontana
Amyloidosis Foundation
5
Michele Boldrini
Foundation Center
6
Rishi Patel
Texas Tech University
7
Ricardo Correa
Federal Reserve Board of Governors
8
Diana Bonderman
Medical University of Vienna
9
Torbjörn Sundström
Umeå University
10
Giulia Zumbo
University of Naples Federico II

Papers

1
Efficacy and Safety of Acoramidis in Transthyretin Amyloid Cardiomyopathy
New England Journal of Medicine|2024
461 cit.
2
SGLT2 Inhibitor Therapy in Patients With Transthyretin Amyloid Cardiomyopathy
Journal of the American College of Cardiology|2024
139 cit.
3
Sex differences among patients with transthyretin amyloid cardiomyopathy – from diagnosis to prognosis
European Journal of Heart Failure|2022
96 cit.
4
The rising tide lifts some interest rates: climate change, natural disasters, and loan pricing
International Finance Discussion Paper|2022
68 cit.
5
Monitoring tafamidis treatment with quantitative SPECT/CT in transthyretin amyloid cardiomyopathy
European Heart Journal - Cardiovascular Imaging|2023
66 cit.
6
Multi-Imaging Characterization of Cardiac Phenotype in Different Types of Amyloidosis
JACC. Cardiovascular imaging|2022
53 cit.
7
Impact of Tafamidis and Optimal Background Treatment on Physical Performance in Patients With Transthyretin Amyloid Cardiomyopathy
Circulation Heart Failure|2022
36 cit.
8
Tracking Multiorgan Treatment Response in Systemic AL-Amyloidosis With Cardiac Magnetic Resonance Derived Extracellular Volume Mapping
JACC. Cardiovascular imaging|2023
36 cit.
9
Impact of tafamidis on myocardial strain in transthyretin amyloid cardiomyopathy
Amyloid|2022
28 cit.
10
Myocardial structural and functional changes in cardiac amyloidosis: insights from a prospective observational patient registry
European Heart Journal - Cardiovascular Imaging|2023
23 cit.

Current Senior Leaders

Wrote the book, still writing it

Researchers

1
Jeffery W. Kelly
Scripps Research Institute
2
Giampaolo Merlini
University of Pavia
3
Per Westermark
Uppsala University
4
Philip N. Hawkins
The Royal Free Hospital
5
Morie A. Gertz
Medical University of South Carolina
6
Mark B. Pepys
University College London
7
Ole B. Suhr
Umeå University
8
Dennis J. Selkoe
Brigham and Women's Hospital
9
Charles Glabe
University of California, Irvine
10
Claudio Rapezzi
University of Ferrara

Papers

1
Naturally secreted oligomers of amyloid β protein potently inhibit hippocampal long-term potentiation in vivo
Nature|2002
4.3k cit.
2
Common Structure of Soluble Amyloid Oligomers Implies Common Mechanism of Pathogenesis
Science|2003
4.1k cit.
3
Amyloid-β protein dimers isolated directly from Alzheimer's brains impair synaptic plasticity and memory
Nature Medicine|2008
3.7k cit.
4
Patisiran, an RNAi Therapeutic, for Hereditary Transthyretin Amyloidosis
New England Journal of Medicine|2018
2.9k cit.
5
Tafamidis Treatment for Patients with Transthyretin Amyloid Cardiomyopathy
New England Journal of Medicine|2018
2.7k cit.
6
Improved survival in multiple myeloma and the impact of novel therapies
Blood|2007
2.3k cit.
7
Nonbiopsy Diagnosis of Cardiac Transthyretin Amyloidosis
Circulation|2016
2k cit.
8
Two transmembrane aspartates in presenilin-1 required for presenilin endoproteolysis and γ-secretase activity
Nature|1999
1.9k cit.
9
Amyloid β-peptide is produced by cultured cells during normal metabolism
Nature|1992
1.9k cit.
10
Mutation of the β-amyloid precursor protein in familial Alzheimer's disease increases β-protein production
Nature|1992
1.7k cit.

Reagents for Amyloidosis: Diagnosis, Treatment, Outcomes

Citation-validated products used in this field

🔥 Trending

Gaining adoption fast

⭐ Top Rated

Best all-around

Cell Signaling Technology

PathScan® Total eIF2 alpha Sandwich ELISA Kit

#7952$66,129,740
View Evidence →
Cell Signaling TechnologyEvidence 66

Rab1A (D3X9S) Rabbit Monoclonal Antibody

#13075$161,351
View Evidence →
Agilent/Dako

Amyloid A

#M0759
View Evidence →

🌟 All-Time

Most validated

Agilent/Dako

Prealbumin (Transthyretin)

Cited in 19 papers
#A0002
View Evidence →
Cell Signaling Technology

Basigin/EMMPRIN (E1S1V) Rabbit Monoclonal Antibody

#13287$168,369
View Evidence →
Cell Signaling TechnologyEvidence 64

INCENP (P240) Antibody

#2807$317
View Evidence →